Crystallographic analysis of Anticalin® targeting CTLA-4 confirms the excellent suitability of Pieris' lipocalin scaffold to develop superior biotherapeutics
Freising-Weihenstephan/Germany (ots) - Crystallographic analysis of Anticalin® targeting CTLA-4 confirms the excellent suitability of Pieris' lipocalin scaffold to develop superior biotherapeutics Pieris AG, a biopharmaceutical company developing therapeutic products comprising Anticalins®, a novel ...